ESMO

Immunotherapy
#ESMO #Immunotherapy #Oncology #Ovarian cancer #Phase I trial #TILT Biotherapeutics

TILT reports encouraging data at ESMO

Biotechnology company TILT Biotherapeutics has presented encouraging results for its TILT-123 therapy at the European Society for Medical Oncology (ESMO) Congress 2026. The company reported on the Phase Ib portion of its PROTA study, which is evaluating TILT-123 (igrelimogene litadenorepvec) in combination with MSD’s anti-PD-1 therapy Keytruda… Read More

#Cancer Research #News

Gut microbiome
#ESMO #Gut microbiome #Microbiotica #Oncology #Phase I trial

Trial data presented at ESMO support cancer microbiome therapy

Microbiotica has presented clinical data with encouraging efficacy from its Phase Ib MELODY-1 trial of MB097, a precision microbiome therapeutic for patients with advanced melanoma.  The data were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026.  The MELODY-1 trial… Read More

#Cancer Research #Editor's Choice #News #Trending News

Cancer cell
#Breast cancer #ESMO #NEC Bio #Oncology #Phase II trial

NEC presents Phase I/II results for individualised oral neoantigen therapy

NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC).   The findings were presented in an e-poster at the ESMO Congress… Read More

#Cancer Research #News #Trending News

Cancer cell
#Cancer #Drug development #ESMO #Liver disease #Oncology

Autotaxin inhibition: unlocking new frontiers in cancers and beyond 

Richard Staines reviews the emergence of autotaxin (ATX) inhibition as a transformative approach in oncology, with the potential to expand into other diseases, including liver malignancies.  Autotaxin (ATX) inhibition is emerging as a promising therapeutic strategy in oncology, with potential relevance to chronic liver disease and beyond. Although early trials in idiopathic pulmonary fibrosis (IPF)… Read More

#Exclusive Content

Monoclonal antibody
#ESMO #Innovent #Monoclonal antibodies #Oncology #Solid tumours

Innovent updates ESMO 2024 on mAbs in solid tumours

Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress. In a Phase I/II study in advanced solid tumours, IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) has demonstrated an excellent safety profile. A total of 368 participants… Read More

#News #Trending News

Cancer metastasis
#Cancer therapeutics #Clinical trials #ESMO #Events #Oncology

The latest breakthroughs in cancer research

The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More

#Cancer Research #News #Trending News

Gastrointestinal tract
#Cancer #Clinical trials #Drug development #ESMO #Gastrointestinal #Redx Pharma #Wnt inhibition

Redx Pharma reports on zamaporvint cancer treatment trials 

Redx Pharma has announced data from all Phase II clinical trial modules of zamaporvint (RXC004), a potent, selective, orally-active Porcupine inhibitor in development for Wnt-ligand dependent, hard-to-treat gastrointestinal (GI) cancers.   These data, presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress, were from… Read More

#Cancer Research #News

Paris
#AI #Antibody drug conjugate (ADC) #DNA #ESMO #ESMO Targeted Anticancer Therapies Congress 2024 #RNA #Storm Therapeutics

Conversations from ESMO Targeted Anticancer Therapies Congress 2024 

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. Rausch gave an update on the latest developments… Read More

#Exclusive Content

Colorectal cancer
#Bowel cancer #Cancer research #Cidara #ESMO #Immuno-oncology #Oncology #Preclinical development

Drug-Fc conjugates exhibit robust anti-tumour activity

A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We are thrilled to be presenting promising preclinical data on our novel multi-specific… Read More

#Cancer Research #News

ESMO 2023
#Cancer research #Clinical trials #ESMO #Oncology

Breaking clinical trial news from ESMO 2023

The European Society for Medical Oncology Meeting (ESMO) 2023 took place from 20-24 October in Madrid, Spain. Many drug discovery companies took the opportunity to share their latest cancer research findings. Axicabtagene ciloleucel, Kite Two indirect comparative analyses of CAR T-cell therapy axicabtagene ciloleucel vs. bispecific… Read More

#Cancer Research #News #Trending News

#ESMO #European Society for Medical Oncology #Tumours

New treatment hope for patients with rare tumours

Ayala Pharmaceuticals has revealed positive interim results from its ongoing RINGSIDE Pivotal Phase II and III clinical trial into gamma-secretase inhibitor AL102 in desmoid tumours. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2022 by Professor Robin Jones, MD, Head of the Sarcoma Unit at… Read More

#News